NASDAQ · ALDX
Healthcare · Biotechnology
$0.92
Down-$0.01 (-0.84%)
Updated Oct 7, 2026, 12:01 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALDX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ALDX closed at $0.92 after 20 trading sessions, down 40.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.18 | $1.185 | $0.8976 | $0.9237 | 7.03M |
| Oct 2, 2026 | $1.31 | $1.31 | $1.15 | $1.17 | 2.28M |
| Oct 1, 2026 | $1.26 | $1.305 | $1.195 | $1.29 | 1.21M |
| Sep 30, 2026 | $1.34 | $1.35 | $1.22 | $1.23 | 1.65M |
| Sep 29, 2026 | $1.17 | $1.44 | $1.16 | $1.32 | 5.46M |
| Sep 28, 2026 | $1.18 | $1.22 | $1.15 | $1.16 | 1.02M |
| Sep 25, 2026 | $1.23 | $1.28 | $1.195 | $1.205 | 644.93K |
| Sep 24, 2026 | $1.35 | $1.35 | $1.22 | $1.22 | 838.7K |
| Sep 23, 2026 | $1.40 | $1.40 | $1.33 | $1.35 | 633.73K |
| Sep 22, 2026 | $1.37 | $1.40 | $1.3506 | $1.395 | 429.89K |
| Sep 21, 2026 | $1.37 | $1.3896 | $1.32 | $1.35 | 495.07K |
| Sep 18, 2026 | $1.40 | $1.40 | $1.345 | $1.36 | 367.72K |
| Sep 17, 2026 | $1.39 | $1.435 | $1.37 | $1.38 | 394.92K |
| Sep 16, 2026 | $1.38 | $1.40 | $1.355 | $1.37 | 791.86K |
| Sep 15, 2026 | $1.45 | $1.45 | $1.345 | $1.37 | 833.61K |
| Sep 14, 2026 | $1.35 | $1.49 | $1.3475 | $1.46 | 1.17M |
| Sep 11, 2026 | $1.48 | $1.48 | $1.33 | $1.34 | 1.57M |
| Sep 10, 2026 | $1.48 | $1.505 | $1.46 | $1.46 | 552.54K |
| Sep 9, 2026 | $1.53 | $1.535 | $1.495 | $1.50 | 544.21K |
| Sep 8, 2026 | $1.47 | $1.55 | $1.47 | $1.54 | 721.82K |
The latest Smart Investors Daily articles mentioning ALDX.
Company
Market Activity
Research & News
ALDX research
Company profile and research snapshot.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 29, 2026 | BTIG | Buy | — |
| Mar 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 10, 2025 | BTIG | Buy | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 30, 2026
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
SeekingAlpha · Sep 30, 2026
Yahoo · Sep 29, 2026
Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c
Yahoo · Sep 29, 2026
Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of New Drugs expected in the fourth quarter of 2026. Key Investor TakeawaysAldeyra Therapeutics (NASDAQ:ALDX) plans to submit a Formal Dispute Resolution Request seeking to appeal the FDA’s March 16, 2026 Complete Response Letter for reproxalap.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALDX.
